Ricks to Succeed Lechleiter at Lilly

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

After 37 years, eight as chief executive officer, John Lechleiter has announced plans to retire from Indianapolis-based Eli Lilly and Co. at the end of the year. The pharmaceutical maker says Senior Vice President Dave Ricks (pictured) will take the helm January 1 and become board chair June 1. Lechleiter, who currently leads the company and the board, will serve as non-executive chairman of the board through May 31. Lechleiter calls it a "logical time" to make the change, as the company continues to navigate a new era that follows a string of patent expirations.  Ricks’ successor as president of Lilly Bio-Medicines, a position he has held since 2012, will be announced at a later date.